Yousefirizi, Fereshteh http://orcid.org/0000-0001-5261-6163
Klyuzhin, Ivan S. http://orcid.org/0000-0003-0141-7628
O, Joo Hyun
Harsini, Sara http://orcid.org/0000-0001-6196-6982
Tie, Xin
Shiri, Isaac http://orcid.org/0000-0002-5735-0736
Shin, Muheon
Lee, Changhee
Cho, Steve Y. http://orcid.org/0000-0003-2724-7778
Bradshaw, Tyler J. http://orcid.org/0000-0001-9549-7002
Zaidi, Habib http://orcid.org/0000-0001-7559-5297
Bénard, François http://orcid.org/0000-0001-7995-3581
Sehn, Laurie H. http://orcid.org/0000-0003-1860-9765
Savage, Kerry J. http://orcid.org/0000-0002-5835-9863
Steidl, Christian http://orcid.org/0000-0001-9842-9750
Uribe, Carlos F. http://orcid.org/0000-0003-3127-7478
Rahmim, Arman http://orcid.org/0000-0002-9980-2403
Funding for this research was provided by:
Canadian Institutes of Health Research (PJT-173231)
Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-06467)
GE Healthcare
Microsoft for Health
Article History
Received: 4 October 2023
Accepted: 15 January 2024
First Online: 8 February 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The retrospective study was conducted with the following ethics numbers: H19-01611 for the PMBCL study and H19-01866 for the DLBCL study and H19-001611 for Hodgkin study at BC Cancer, as well as KC11EISI0293 for the DLBCL study at Seoul St. Mary’s Hospital and UW2016-0418 for DLBCL and Hodgkin’s cases at University of Wisconsin.
: Ivan Klyuzhin, Carlos Uribe, and Arman Rahmim are co-founders of Ascinta Technologies Inc.